September 27, 2017 / 7:11 AM / in 24 days

BRIEF-Novo Nordisk's Tresiba approved in China

Sept 27 (Reuters) - NOVO NORDISK SAYS

* THE CHINA FOOD AND DRUG ADMINISTRATION (CFDA) HAS APPROVED NEW-GENERATION BASAL INSULIN TRESIBA (INSULIN DEGLUDEC) FOR THE TREATMENT OF DIABETES IN CHINA.

* TRESIBA IS EXPECTED TO LAUNCH IN CHINA IN Q1 2018.

* CHINA HAS OVER 100 MILLION PEOPLE LIVING WITH DIABETES, AND THE NUMBER IS EXPECTED TO GROW TO MORE THAN 150 MILLION PEOPLE BY 2040. FURTHER COMPANY COVERAGE: (Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below